Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma.

about

Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma.

Item

http://www.wikidata.org/entity/Q47606157

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@en

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@nl

type

Item

label

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@en

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@nl

prefLabel

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@en

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@nl

P1476

Matrix metallopeptidase 9 targ ...... ilybin-inhibited osteosarcoma.

@en

P2093

Frankie Leung

http://www.w3.org/2001/XMLSchema#string

Kelvin S C Cheung

http://www.w3.org/2001/XMLSchema#string

Tianhao Sun

http://www.w3.org/2001/XMLSchema#string

William W Lu

http://www.w3.org/2001/XMLSchema#string

Zhi-Li Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies

Wnt/β-catenin signalling in prostate cancer

Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells

Intracellular and extracellular microRNA: An update on localization and biological role.

Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.

Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells

Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: review and meta-analysis.

The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.

miR-375-3p negatively regulates osteogenesis by targeting and decreasing the expression levels of LRP5 and β-catenin

Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.

P304

262-271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MC.22753

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29068478

http://www.w3.org/2001/XMLSchema#string